Usage of preimplantation genetic diagnosis (PGD) to screen embryos for aneuploidy and genetic diseases is increasing continuously. PGD can benefit people at risk for passing on a genetic disease or condition to the next generation. PGD test can be done for more than 100 different genetic conditions. PGD applications are growing for screening embryos for susceptibility to cancer, diagnosing late?onset diseases, HLA?matching in existing children, and gender selection. The number of people suffering from genetic disorders is increasing rapidly, and at the same time, PGD is considered 98% accurate in determining genetic abnormalities. Increase in patient awareness about PGD technique and rise in prevalence of genetic disorders among infants has led to high demand fora PGD along with IVF procedure. PGD is least troublesome for a couple already going through IVF for infertility due to advanced maternal age. Prevalence of diseases such as hereditary breast cancer, diabetes, asthma, and congenital heart diseases is rising every year across the world. The added cost of embryo biopsy and karyotyping could be justified if these produce a marked improvement in pregnancy rates.
Request a Sample Copy of the Report @ http://www.mrrse.com/sample/1674
The preimplantation genetic diagnosis (PGD) market in Asia has been divided into three major segments: test type, end-user, and geography. Based on test type, the market has been sub-segmented into aneuploidy screening, chromosomal aberrations, gender selection, HLA typing, single gene disorder, and X-linked diseases. Aneuploidy screening during prenatal testing has a major disadvantage; if the chromosomal abnormality were detected in the fetus, the pregnancy would be terminated. However, this drawback is efficiently overcome by opting for preimplantation genetic diagnosis, as genetic screening for aneuploidy is performed before the embryo is implanted and pregnancy is conceived. The aneuploidy screening segment accounted for the largest share of 35% of the PGD market in Asia in 2014. Based on end-user, the market has been segmented into fertility clinics, health care facilities (including hospitals, diagnostic centers, and health care facilities), and academic institutes and research centers.
Inquiry on this report @ http://www.mrrse.com/enquiry/1674
Asia includes developing economies, such as India, China, Indonesia, Vietnam, Australia, Israel, and Singapore, which offer significant opportunities for growth of PGD in the health care sector. According to the Malaysian Medical Council (MMC) guidelines, creating designer babies by PGD is specifically prohibited. More Asians are heading to countries such as Thailand for medical procedures that allow them to choose their babies’ gender. Geographically, the market has been studied and estimated for Asia covering South Eastern Asia, Eastern Asia, Southern Asia, Central Asia, and Western Asia. South Eastern Asia includes Indonesia, Malaysia, the Philippines, Singapore, Thailand, and Rest of SEA. Eastern Asia comprises China, Japan, South Korea, and Rest of Eastern Asia. Southern Asia constitutes India, Sri Lanka, and Rest of Southern Asia. Western Asia includes Israel, Turkey, Jordan, Saudi Arabia, the United Arab Emirates, and Rest of Western Asia. Eastern Asia accounted for the largest share of the PGD market in Asia in 2014. The PGD market in this region is expected to grow rapidly during the forecast period due to factors such as the presence of untapped opportunities in the health care sector, rising medical tourism and increasing health care awareness. According to Xinhua, a news agency in China, infertility rate in the country rose from 3% in 1990 to 12.5% in 2010. In India, the Ministry of Family Health and Welfare regulates “The Pre-Conception and Prenatal Diagnostic Techniques (Prohibition of Sex Selection) Act, 1994”, which has been revised and updated on a timely basis. Similarly, according to The Times of India, an India-based newspaper, 10% of the country’s population was suffering from infertility in 2013.
Read Complete Report with TOC @ http://www.mrrse.com/asia-preimplantation-genetic-diagnosis-market
Major players in this market are Genesis Genetics (U.S.), Genea Limited (Australia), Illumina, Inc. (U.S.), Laboratory Corporation of America Holdings (U.S.), Natera, Inc. (U.S.), PerkinElmer, Inc.(U.S.), Quest Diagnostics Incorporated (U.S.), Reprogenetics (U.S.), and Reproductive Genetics Innovations LLC (U.S.).
90 State Street,
Albany NY – 12207